Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Wiley 2020-07-01
Cyfres:	Endocrinology, Diabetes & Metabolism
Pynciau:	albuminuria CCR2 diabetes kidney MCP‐1 propagermanium
Mynediad Ar-lein:	https://doi.org/10.1002/edm2.159
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!